Patents by Inventor Nicole Joy BEDKE

Nicole Joy BEDKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS
    Publication number: 20230416335
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: May 26, 2023
    Publication date: December 28, 2023
    Inventors: Philip William ADDIS, Nicole Joy BEDKE, Lucie BOUARD, Stephen HARPER, Nathaniel LIDDY, Tara MAHON, Ronan Pádraic O'DWYER
  • T cell receptors
    Patent number: 11718657
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: August 8, 2023
    Assignee: Immunocore Limited
    Inventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
  • T cell receptors
    Patent number: 11427624
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: August 30, 2022
    Assignee: Immunocore Limited
    Inventors: Philip William Addis, Nicole Joy Bedke, Lucie Bouard, Stephen Harper, Nathaniel Liddy, Tara Mahon, Ronan Pádraic O'Dwyer
  • T CELL RECEPTORS
    Publication number: 20220177541
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 9, 2022
    Inventors: Philip William ADDIS, Nicole Joy BEDKE, Lucie BOUARD, Stephen HARPER, Nathaniel LIDDY, Tara MAHON, Ronan Pádraic O'DWYER
  • T CELL RECEPTORS
    Publication number: 20210355188
    Abstract: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
    Type: Application
    Filed: June 19, 2018
    Publication date: November 18, 2021
    Inventors: Philip William ADDIS, Nicole Joy BEDKE, Lucie BOUARD, Stephen HARPER, Nathaniel LIDDY, Tara MAHON, Ronan Pádraic O'DWYER